Imagine a technology so advanced it engineers the immune system to hunt cancer with ruthless precision. $NWBO’s αDC1 platform—25 years in the making—is doing just that, treating dying patients RIGHT NOW in Phase 2 trials backed by $25.7M in federal funding. This isn’t just immunotherapy; it’s a revolution that turns “cold,” untreatable tumors into “hot,” vulnerable targets. With potential to boost response rates from 20% to 40-60%+, it could double the $30B+ market. Buckle up—let’s dive into a breakthrough that’s rewriting cancer’s rules. (Figure at end) The Science of Hope: αDC1 isn’t a drug; it’s a weaponized immune army. From a simple blood draw, patient monocytes are isolated and transformed over 7 days into elite dendritic cells using a precise cocktail (IL-4, GM-CSF, TNF-α, IFN-α, Poly I:C, IFN-γ). These cells resist tumor tricks, while Chemokine-Modulating Regimens (CKM) prep the battlefield with Interferon alpha, Rintatolimod, and Celecoxib to crush immune suppression. With >80% viability and >90% purity, this isn’t guesswork—it’s engineered warfare against cancer. Ready for what’s next? #Immunotherapy

$NWBO investors should be aware of the two other candidates in development that the UK's NICE is evaluating for glioblastoma. The first is Asunercept. It shows promise. In 2019 they reported that 7% of pts survived 5 years. Recall that 13% of DCVax pts survive 5 years ... so they are not very comparable, and NICE is all about comparisons. The second one is ERC1671, which is a tumor lysate injection (mechanistically related to DCVax). It showed great promise in its Phase 2 trial which was suspended and the company was told to do a Phase 3 trial...